pharmaphorum.com
Cure8 news brief
Why This Matters
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to current biologics and changes the competitive landscape among IL‑23 therapies.
Who Should Pay Attention
Adults with Crohn’s disease or ulcerative colitis, patients considering or already on biologic/IL‑23 therapies, gastroenterologists, and researchers tracking IBD drug development and market access.
Study Snapshot
Story typeResearch news
Evidence typeRegulatory update
Source depthFull source text
What To Know
Tremfya (guselkumab) has received FDA approval for Crohn’s disease, giving Johnson & Johnson an IL-23 option available in both IV and subcutaneous formulations for IBD.
The article notes J&J’s claims about Tremfya’s year‑one remission and endoscopic response on a fully subcutaneous regimen and references the GRAVITI and GALAXI studies, including a reported superiority to Stelara (ustekinumab) on pooled endoscopic endpoints in GALAXI.
The piece places Tremfya in the competitive context of other IL‑23 drugs—Skyrizi (risankizumab), Omvoh (mirikizumab), and Ilumya (tildrakizumab)—and mentions commercial sales and market projections.
Keep In Mind
This is a regulatory approval and commercial analysis based on company statements and pivotal trials (GRAVITI, GALAXI). The article reports company claims about efficacy and cites head‑to‑head trial results; readers should consult primary trial publications and clinical guidance for detailed efficacy and safety data.
Approval does not imply one drug is superior for all patients.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationpharmaphorum.com
Indexed viaBing News
Source typeResearch news
PublishedMar 21, 2025, 4:16 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...